List of Asthma Inhalers, Ingredients and How They Work
For anyone with asthma, it's important to know the treatment options available and how they work to help you breathe better. Asthma medications are used for either quick relief of symptoms or long-term control, with the goal of reducing or preventing symptoms. Major types of inhaled asthma drugs include anti-inflammatory medications for long-term control and bronchodilators, which are either short- or long-acting. Asthma inhalers deliver these medications directly to the lungs, which reduces the risk of side effects in other parts of the body. Most people with asthma need both quick-relief and long-term medications to control of their symptoms.
If you are experiencing serious medical symptoms, seek emergency treatment immediately.
Inhalers for Quick Relief and Flareups
Sudden or worsening asthma symptoms typically occur when the lung airways constrict, obstructing airflow. Short-acting beta 2 agonists (SABAs) are bronchodilators that provide rapid relief of asthma symptoms by relaxing the small airways. As the airways expand, airflow improves and symptoms decrease. Guidelines issued in 2007 by the National Institutes of Health (NIH) recommend inhaled SABAs as first-choice treatment during an asthma attack. Examples include albuterol (ProAir, Proventil, Ventolin) and levalbuterol (Xopenex). Inhaled ipratropium (Atrovent) -- an anticholinergic medication -- inhibits large airway constriction. Ipratropium doesn’t work as fast as SABAs, but is sometimes used with a SABA for severe asthma flareups.
- Sudden or worsening asthma symptoms typically occur when the lung airways constrict, obstructing airflow.
- Short-acting beta 2 agonists (SABAs) are bronchodilators that provide rapid relief of asthma symptoms by relaxing the small airways.
Inhalers for Long-Term Control
List of Nebulizer Medications and Ingredients
Learn More
Airway inflammation is a hallmark characteristic of asthma. Inhaled corticosteroids (ICSs) are anti-inflammatory drugs that reduce airway swelling and prevent excess mucus production for long-term control of asthma. NIH's National Asthma Control Initiative notes that ICSs are the most effective drugs for long-term management of asthma 2. Examples include: - beclomethasone (Qvar) - budesonide (Pulmicort) - flunisolide (Aerospan) - fluticasone (Flovent, Veramyst) - mometasone (Asmanex).
Cromolyn sodium is a mast cell stabilizer, another class of inhaled drugs for long-term asthma control. Cromolyn prevents cells from releasing substances that cause airway inflammation, and is sometimes recommended for people whose asthma is not well controlled with an ICS.
- Airway inflammation is a hallmark characteristic of asthma.
- Cromolyn sodium is a mast cell stabilizer, another class of inhaled drugs for long-term asthma control.
Combination Inhalers
Some asthma inhalers contain a combination of medications to help people with asthma control their symptoms. The 2007 NIH asthma guidelines recommend adding a long-acting beta 2-agonist (LABA) -- such as salmeterol (Serevent) and formoterol (Foradil, Perforomist) -- to an ICS for people whose asthma is not well controlled with an ICS alone. The LABA prevents airway constriction, but using a LABA alone is not recommended. ICS plus LABA inhalers reduce inflammation and keep the airways relaxed for long-term asthma control. Examples of these combination inhalers include: - fluticasone and salmeterol (Advair) - budesonide and formoterol (Symbicort) - mometasone and formoterol (Dulera).
- Some asthma inhalers contain a combination of medications to help people with asthma control their symptoms.
- The 2007 NIH asthma guidelines recommend adding a long-acting beta 2-agonist (LABA) -- such as salmeterol (Serevent) and formoterol (Foradil, Perforomist) -- to an ICS for people whose asthma is not well controlled with an ICS alone.
Warnings and Precautions
Long-Term Effects of Overuse of an Inhaler for Asthma
Learn More
It's important to take asthma medications as directed by your doctor. Quick-relief inhalers are used during an asthma attack. Long-term controller medications are not effective for relief during an asthma attack. If your symptoms worsen or do not improve with use of your quick-relief inhaler, seek immediate medical attention.
Talk with your doctor about your asthma medications if you are pregnant or breastfeeding, as some may be better than others for you and your baby. Keep in mind, however, that the advantages of treating an active asthma attack outweigh the potential risks of quick-relief and long-term control asthma medications.
Medical adviser: Shilpi Agarwal, M.D.
- It's important to take asthma medications as directed by your doctor.
- Talk with your doctor about your asthma medications if you are pregnant or breastfeeding, as some may be better than others for you and your baby.
Related Articles
References
- Guidelines for the Diagnosis and Management of Asthma Summary Report 2007; National Asthma Education and Prevention Program Expert Panel Report 3
- National Asthma Control Initiative: Inhaled Corticosteriods: Keep Airways Open
- National Heart, Lung, and Blood Institute: Asthma Care Quick Reference: Diagnosing and Managing Asthma
- Pharmacological Reviews: Pharmacology and Therapeutics of Bronchodilators
- Centers for Disease Control and Prevention. Consumer Information. Asthma.
- Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma.
- Franks TJ, Burton DL, Simpson MD. Patient medication knowledge and adherence to asthma pharmacotherapy: a pilot study in rural Australia. Ther Clin Risk Manag. 2005;1(1):33–38. doi:10.2147/tcrm.1.1.33.53598
- Vernon MK, Wiklund I, Bell JA, Dale P, Chapman KR. What do we know about asthma triggers? A review of the literature. J Asthma. 2012;49(10):991-8. doi:10.3109/02770903.2012.738268
- Jiménez-ruiz CA, Andreas S, Lewis KE, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015;46(1):61-79. doi:10.1183/09031936.00092614
- Mastronarde JG. Is There a Relationship Between GERD and Asthma? Gastroenterol Hepatol (N Y). 2012;8(6):401-3.
- Dogra S, Kuk JL, Baker J, Jamnik V. Exercise is associated with improved asthma control in adults. Eur Respir J. 2011;37(2):318-23. doi:10.1183/09031936.00182209
- Barnes PJ. Inhaled Corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514-540. doi:10.3390/ph3030514
- Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J. 2009;33(1):3-5. doi:10.1183/09031936.00163408
- Gadde D, Creticos P, Beakes D, et al. Adverse Effects Associated with Leukotriene Antagonist Therapy. Journal of Allergy and Clinical Immunology. 2010;125(2). doi:10.1016/j.jaci.2009.12.266
- Sorkness CA, Schend VA. Monitoring for Side Effects from Treatment. Clinical Asthma. 2008:313-319. doi:10.1016/b978-032304289-5.10035-9
- Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for severe asthma. Med J Aust. 2018;209(S2):S18-S21. doi:10.5694/mja18.00134
- U.S. National Library of Medicine. Asthmanefrin. 2017.
- NIH National Center for Complementary and Integrative Health. Asthma: In Depth. Updated September 24, 2017.
- Freitas DA, Holloway EA, Bruno SS, Chaves GS, Fregonezi GA, Mendonça KP. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2013;(10):CD001277. doi:10.1002/14651858.CD001277.pub3
- Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011;365(2):119-26. doi:10.1056/NEJMoa1103319
- Medici TC, Grebski E, Wu J, Hinz G, Wüthrich B. Acupuncture and bronchial asthma: a long-term randomized study of the effects of real versus sham acupuncture compared to controls in patients with bronchial asthma. J Altern Complement Med. 2002;8(6):737-50. doi:10.1089/10755530260511748
- National Center for Complementary and Integrative Health. Asthma: In Depth.
- Wechsler ME, Kelley JM, Boyd IOE, et al. Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in Asthma. New England Journal of Medicine. 2011;365(2):119–126. doi:10.1056/NEJMoa1103319
- Wilhelm CP, Chipps BE. Bronchial Thermoplasty: A Review of the Evidence. Ann Allergy Asthma Immunol. 2016;116:92-98. doi:10.1016/j.anai.2015.11.002
- Centers for Disease Control and Prevention. Consumer Information. Asthma.
- Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma.
Writer Bio
Angela L. Davis is a postdoctoral research scientist at the Bio5 institute in Tucson, Ariz. Her research articles have been published in peer reviewed scientific journals, including the Journal of Biological Chemistry. She holds a Doctorate degree in pharmaceutical sciences from the University of Arizona.